Insmed Incorporated INSM
119.49 USD +3.39 (+2.92%)
At closeNov 10, 2026, 4:41 PM EST
119.49 0.00 0.00%
After hours · Nov 10, 4:41 PM ET
113.81 Day range 119.84
90.39 52-week range 212.75
- YTD
- -31.34%
- 1 year
- -37.74%
News
benzinga.com Here’s How Much You Would Have Made Owning Insmed Stock In The Last 5 Years Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 21.49% on an annualized basis producing an average annual return of 31.4%. Currently, Insmed has a market capitalization of…
zacks.com 4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
seekingalpha.com Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales…
247wallst.com Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades…
benzinga.com HC Wainwright & Co. Assumes Insmed at Buy, Announces Price Target of $220 HC Wainwright & Co. analyst Matthew Caufield assumes Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $220.
prnewswire.com Insmed to Present at November and December 2026 Investor Conferences BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform…
benzinga.com Guggenheim Maintains Buy on Insmed, Lowers Price Target to $201 Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $205 to $201.
seekingalpha.com Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer…
zacks.com INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
marketbeat.com What Insmed (INSM) Said on Its Q3 Earnings Call Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
zacks.com Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
benzinga.com Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
zacks.com Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates Insmed (INSM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $1.75 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M Estimate Insmed (NASDAQ:INSM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.43) by 6.98 percent. This is a 73.71 percent increase over losses of $(1.75) per…
benzinga.com Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B Est Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.700 billion-$1.870 billion to $1.810 billion-$1.870 billion vs $1.801 billion estimate.
prnewswire.com Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update —Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second…
defenseworld.net Citizens Financial Group Inc. RI Makes New Investment in Insmed, Inc. $INSM Citizens Financial Group Inc. RI acquired a new position in shares of Insmed, Inc. (NASDAQ: INSM) during the third quarter, according to its most recent filing with the Securities and Exchange…
benzinga.com $100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.42% on an annualized basis producing an average annual return of 24.03%. Currently, Insmed has a market capitalization of…
zacks.com Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213 Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $218 to $213.
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
prnewswire.com Insmed Appoints Two New Directors to Its Board —Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J.,…
prnewswire.com Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan —BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026…
prnewswire.com Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 —Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of…
prnewswire.com Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 —Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary…
defenseworld.net Perpetual Ltd Acquires 5,760 Shares of Insmed, Inc. $INSM Perpetual Ltd raised its holdings in shares of Insmed, Inc. (NASDAQ: INSM) by 164.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and…
benzinga.com This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
benzinga.com This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
benzinga.com HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.
zacks.com INSM Stock Slides on CFO Exit, Reiterates '26 Sales View Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.- benzinga.com $100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 17.45% on an annualized basis producing an average annual return of 29.54%. Currently, Insmed has a market capitalization of…
benzinga.com Nasdaq 100 Hits Record, Brazil's EWZ Soars 13%: Stock Market Today Nasdaq 100 hits a record as Brazil's EWZ jumps 13% on Bolsonaro's election upset; ISM services prices hit a four-year high and the 10-year yield tops 5.3%.
benzinga.com Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed Insmed Inc. (NASDAQ:INSM) shares are trading lower by almost 7% on Monday as traders digest a CFO transition update alongside a slightly softer risk tone.
benzinga.com Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed Insmed shares slip after CFO Sara Bonstein steps down, reaffirms 2026 financial targets.
benzinga.com Insmed Q2 2026 Earnings Call Transcript Insmed (NASDAQ:INSM) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time…- benzinga.com Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE Reaffirms Full-Year 2026 GuidanceAs Insmed continues to build on its operational excellence and momentum, the Company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25…
- benzinga.com Barclays Maintains Overweight on Insmed, Lowers Price Target to $207 Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.
benzinga.com $1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.06% on an annualized basis producing an average annual return of 24.7%. Currently, Insmed has a market capitalization of…- benzinga.com The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome Inhalation Suspension) For Mycobacterium Avium Complex Lung Disease As Part Of Combination Antibacterial Drug Regimen, With Target Action Date Of January 28, 2027 Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases,…
- benzinga.com Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198 Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.
benzinga.com Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 24.42% on an annualized basis producing an average annual return of 35.99%. Currently, Insmed has a market capitalization of…- benzinga.com If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of…
benzinga.com Biotech Is Booming, But These 2 Stocks Missed the Memo The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
benzinga.com JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175 JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.
benzinga.com Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195 Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.- benzinga.com $1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of…
benzinga.com Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205 Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.